Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype
- PMID: 2495208
- DOI: 10.1038/clpt.1989.40
Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype
Abstract
Single oral 10 mg doses of diazepam and demethyldiazepam were given on different occasions to 16 healthy subjects. The subjects included four poor hydroxylators of debrisoquin and three poor hydroxylators of mephenytoin. There was a correlation between the total plasma clearance of diazepam and demethyldiazepam (rs = 0.83; p less than 0.01). There was no relationship between benzodiazepine disposition and debrisoquin hydroxylation. Poor hydroxylators of mephenytoin had less than half the plasma clearance of both diazepam (p = 0.0008) and demethyldiazepam (p = 0.0001) compared with extensive hydroxylators of mephenytoin. The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001). There was no significant difference in volume of distribution of the benzodiazepines between the phenotypes. This study shows that the metabolism of both diazepam (mainly demethylation) and demethyldiazepam (mainly hydroxylation) is related to the mephenytoin, but not to the debrisoquin, hydroxylation phenotype.
Similar articles
-
Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.Clin Pharmacol Ther. 1992 Aug;52(2):160-9. doi: 10.1038/clpt.1992.125. Clin Pharmacol Ther. 1992. PMID: 1505151
-
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.Clin Pharmacol Ther. 1989 May;45(5):495-9. doi: 10.1038/clpt.1989.63. Clin Pharmacol Ther. 1989. PMID: 2721104
-
Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.Ther Drug Monit. 1989 Nov;11(6):721-3. doi: 10.1097/00007691-198911000-00019. Ther Drug Monit. 1989. PMID: 2595755
-
Genetic polymorphism of mephenytoin metabolism.Prog Clin Biol Res. 1986;214:139-56. Prog Clin Biol Res. 1986. PMID: 3523505 Review. No abstract available.
-
Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.Psychopharmacol Ser. 1989;7:201-5. doi: 10.1007/978-3-642-74430-3_21. Psychopharmacol Ser. 1989. PMID: 2687858 Review. No abstract available.
Cited by
-
Inhibitors of imipramine metabolism by human liver microsomes.Br J Clin Pharmacol. 1992 Sep;34(3):256-61. doi: 10.1111/j.1365-2125.1992.tb04133.x. Br J Clin Pharmacol. 1992. PMID: 1389950 Free PMC article.
-
Impact of obesity on drug metabolism and elimination in adults and children.Clin Pharmacokinet. 2012 May 1;51(5):277-304. doi: 10.2165/11599410-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22448619 Review.
-
Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism.Eur J Clin Pharmacol. 2004 Aug;60(6):427-30. doi: 10.1007/s00228-004-0789-1. Epub 2004 Jul 1. Eur J Clin Pharmacol. 2004. PMID: 15232663 Clinical Trial.
-
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.Eur J Clin Pharmacol. 2010 Sep;66(9):871-7. doi: 10.1007/s00228-010-0835-0. Epub 2010 May 25. Eur J Clin Pharmacol. 2010. PMID: 20499227
-
Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes.Eur J Clin Pharmacol. 1993;44(6):559-62. doi: 10.1007/BF02440859. Eur J Clin Pharmacol. 1993. PMID: 8405013
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases